IM2PACT

Investigating mechanisms and models predictive of accessibility of therapeutics (IM2PACT) into the brain
IM2PACT logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 12
Grant agreement number
807015

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
9 000 000
EFPIA in kind
8 410 136
Total Cost
17 410 136

Summary

As the name suggests, the blood-brain barrier (BBB) tightly controls access to our brains, allowing nutrients and essential substances through, but blocking pathogens, for example. Getting medicines through this protective shield is a major challenge for drug developers, particularly those developing biopharmaceuticals, which are based on large molecules like proteins and antibodies. The goal of IM2PACT is to advance our understanding of the BBB to facilitate the development of more effective treatments for a range of neurological and metabolic disorders. Specifically, the project aims to develop better models of the BBB so that researchers can study it more easily; investigate the biology of the BBB in both health and disease, and the transport routes across it; and to develop innovative systems capable of delivering medicines to the brain. The project will focus on two major disease areas: neurodegenerative diseases, including Alzheimer and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease and motor neurone disease), vascular dementia, and multiple sclerosis; and metabolism-related diseases (mainly diabetes and obesity).

Participants Show participants on map

EFPIA companies
  • Fujifilm Cellular Dynamics Inc, Madison, United States
  • H. Lundbeck As, Valby, Denmark
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
  • Aarhus Universitet, Aarhus C, Denmark
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Ait Austrian Institute Of Technology GMBH, Wien, Austria
  • Cardiff University, Cardiff, United Kingdom
  • Kobenhavns Universitet, Copenhagen, Denmark
  • Ruprecht-Karls-Universitaet Heidelberg, Heidelberg, Germany
  • Stichting Vumc, Amsterdam, Netherlands
  • Stiftung Tieraerztliche Hochschule Hannover, Hannover, Germany
  • The Open University, Milton Keynes, United Kingdom
  • The University Of Sheffield, Sheffield, United Kingdom
  • Universita Degli Studi Di Modena E Reggio Emilia, Modena, Italy
  • Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Wuerzburg, Germany
  • Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany
  • University Of Dundee, Dundee, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Artemis Bio-Support B.V., Utrecht, Netherlands
  • Mimetas BV, Leiden, Netherlands
  • Neuway Pharma GMBH, Bonn, Germany
  • Pharmacoidea Fejleszto Es Szolgaltato Kft, Szeged, Hungary

CONTACT

Project coordinator
Zameel CADER
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
zameel.cader[at]ndcn.ox.ac.uk